(Q45278471)

11 December 2017

title

A concise display of multiple end points for benefit-risk assessment (English)

1 reference

11 December 2017

B Levitan

1

1 reference

11 December 2017

language of work or name

English

0 references

publication date

24 November 2010

1 reference

Clinical Pharmacology & Therapeutics

11 December 2017

published in

1 reference

11 December 2017

volume

89

1 reference

11 December 2017

issue

1

1 reference

11 December 2017

page(s)

56-59

1 reference

Regulatory challenges, reimbursement, and risk-benefit assessment

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

Compelling or irrelevant? Using number needed to treat can help decide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

The number needed to treat: a clinically useful measure of treatment effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

Lost in transmission--FDA drug information that never reaches clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

Clinical trials design lessons from the CATIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

Confidence intervals for the number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

inferred from DOI database lookup

7 January 2021

based on heuristic

Benefit-risk analysis: a proposal using quantitative methods

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

inferred from DOI database lookup

7 January 2021

based on heuristic

Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.251

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2010.251

1 reference

11 December 2017

1 reference